Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort.

At univariate analysis at 12 months, lymphopenia responders had a lower rate of anti-Sm seropositive patients (17.1% vs 42.2%, p=0.011), higher mean C4 values (11.7±6.2 vs 8.8±4.5 mg/dL, p<0.05) and higher mean±SD baseline lymphocyte counts (0.768±0.195 vs 0.679±0.208 x 10 9 /L, p<0.05) compared with lymphopenia non-responders; lower rates of anti-SSA seropositive patients were found among responders, although this difference narrowly missed statistical significance (45.7% vs 65.6%, p=0.055).

also in 227 other papers